Covered recipient · General Payments record
REYNA MARTIN
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2022–2024
$1,375.12
- Reported across 70 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $519.58 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $147.79 | 9 |
| ABBVIE INC. | $142.45 | 14 |
| Lilly USA, LLC | $62.70 | 4 |
| PFIZER INC. | $55.25 | 2 |
| Abbott Laboratories | $45.03 | 2 |
| Axsome Therapeutics, Inc. | $38.82 | 2 |
| Acerta Pharma LLC | $14.28 | 1 |
| Exact Sciences Corporation | $13.26 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.99 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124852556 | CMS |
| Abbott Laboratories | $21.04 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124852558 | CMS |
| ABBVIE INC. | $6.10 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597791 | CMS |
| ABBVIE INC. | $22.60 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597793 | CMS |
| ABBVIE INC. | $16.04 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597795 | CMS |
| ABBVIE INC. | $13.28 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597797 | CMS |
| ABBVIE INC. | $12.23 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597799 | CMS |
| ABBVIE INC. | $11.49 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597801 | CMS |
| ABBVIE INC. | $9.21 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597803 | CMS |
| ABBVIE INC. | $7.32 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597805 | CMS |
| ABBVIE INC. | $8.29 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597807 | CMS |
| ABBVIE INC. | $4.02 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597809 | CMS |
| ABBVIE INC. | $4.14 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597811 | CMS |
| ABBVIE INC. | $9.26 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597813 | CMS |
| ABBVIE INC. | $10.59 | 11/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597815 | CMS |
| ABBVIE INC. | $7.88 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107597817 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.28 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105382128 | CMS |
| Axsome Therapeutics, Inc. | $24.67 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148402999 | CMS |
| Axsome Therapeutics, Inc. | $14.15 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148403001 | CMS |
| Exact Sciences Corporation | $13.26 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114774574 | CMS |
| Lilly USA, LLC | $14.20 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135934220 | CMS |
| Lilly USA, LLC | $20.29 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135929642 | CMS |
| Lilly USA, LLC | $14.72 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135951732 | CMS |
| Lilly USA, LLC | $13.49 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135920692 | CMS |
| Novo Nordisk Inc | $19.70 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100261019 | CMS |
| Novo Nordisk Inc | $11.33 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100618820 | CMS |
| Novo Nordisk Inc | $19.79 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100509105 | CMS |
| Novo Nordisk Inc | $14.86 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100455922 | CMS |
| Novo Nordisk Inc | $16.66 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100269176 | CMS |
| Novo Nordisk Inc | $14.48 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100469674 | CMS |
| Novo Nordisk Inc | $16.71 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100451958 | CMS |
| Novo Nordisk Inc | $24.92 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100450896 | CMS |
| Novo Nordisk Inc | $9.34 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100229240 | CMS |
| PFIZER INC. | $22.66 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131444375 | CMS |
| PFIZER INC. | $32.59 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131024006 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.